Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.22 USD
Change Today 0.00 / 0.00%
Volume 17.5K
CAPS On Other Exchanges
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

capstone therapeutics corp (CAPS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/11/14 - $0.39
52 Week Low
05/29/15 - $0.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

capstone therapeutics corp (CAPS) Related Businessweek News

No Related Businessweek News Found

capstone therapeutics corp (CAPS) Details

Capstone Therapeutics Corp., a biotechnology company, focuses on developing a pipeline of peptides and other molecules for helping patients with under-served medical conditions. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that play an important role in lipoprotein metabolism, which have competed Phase Ia and Phase 1b/2a clinical trials. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

2 Employees
Last Reported Date: 07/2/15
Founded in 1987

capstone therapeutics corp (CAPS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $135.0K
Chief Medical Officer and Consultant
Total Annual Compensation: $135.0K
Compensation as of Fiscal Year 2014.

capstone therapeutics corp (CAPS) Key Developments

Capstone Therapeutics Corp., Q2 2015 Earnings Call, Aug 13, 2015

Capstone Therapeutics Corp., Q2 2015 Earnings Call, Aug 13, 2015

Capstone Therapeutics Corp. and LipimetiX Development, Inc. Announce Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides

Capstone Therapeutics Corp. and its joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced the conversion of a provisional U.S. Patent application claiming novel, more potent analogs of its lead peptide, AEM-28. The JV has supported research by Dr. G.M. Anantharamaiah at the University of Alabama, Birmingham to identify novel analogs of AEM-28 that demonstrate greater efficacy than the parent peptide and provide new composition of matter patent protection. One of the new, chimeric Apo E mimetic peptides (AEM-28-14), tested in multiple, validated animal models, demonstrates up to 400% greater cholesterol lowering efficacy and a several fold increase in the NOAEL (No Observed Adverse Effect Level) dose, a primary indicator of drug tolerability. The combination of enhanced efficacy and toleration potentially increases the therapeutic window (the range for delivering a safe and efficacious dose) significantly over previous analogs of AEM-28.

Capstone Therapeutics Corp., Q1 2015 Earnings Call, May 28, 2015

Capstone Therapeutics Corp., Q1 2015 Earnings Call, May 28, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPS:US $0.22 USD 0.00

CAPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPS.
View Industry Companies

Industry Analysis


Industry Average

Valuation CAPS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPSTONE THERAPEUTICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at